Singapore Bioimaging Consortium, Agency for Science, Technology and Research (A∗ STAR), 11 Biopolis Way, #07-10 Helios, Singapore 138667.
Department of Physiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore 117456.
Contrast Media Mol Imaging. 2019 Feb 3;2019:2538909. doi: 10.1155/2019/2538909. eCollection 2019.
Peripheral artery disease (PAD) causes narrowing of arteries in the limbs, leading to tissue ischemia, gangrene, and eventually limb amputation. The presence of diabetes greatly exacerbates the course of PAD, accounting for the majority of lower limb amputations. Therapeutic strategies focussing on macrovascular repair are less effective in diabetic patients where smaller vessels are affected, and proangiogenic therapies offer a viable adjunct to improve vascularisation in these at risk individuals. The purpose of the current study was to assess the proangiogenic effects of drugs routinely used to treat cardiovascular disease in a diabetic murine model of hind limb ischemia longitudinally using multimodal imaging.
Diabetic mice underwent surgical intervention to induce hind limb ischemia and were treated with simvastatin, metformin, or a combination orally for 28 days and compared to diabetic and nondiabetic mice. Neovascularisation was assessed using [F]FtRGD PET imaging, and macrovascular volume was assessed by quantitative time of flight MRI. At each imaging time point, VEGF expression and capillary vessel density were quantified using immunohistochemical analysis, and functional recovery and disease progression were assessed.
Combined use of simvastatin and metformin significantly increased neovascularisation above levels measured with either treatment alone. Early angiogenic events were accurately assessed using PET [F]FtRGD, showing maximal retention in the ischemic hind limb by day 8, which translated to a sustained increase in vascular volume at later time points. Immunohistochemical analysis shows that combined therapy significantly increased VEGF expression and capillary density (CD31) in a similar time course and also slowed disease progression while simultaneously improving functional foot use.
Combined treatment with simvastatin and metformin led to a significant improvement in limb angiogenesis, vascular volume, and sustained functional recovery in a diabetic murine model of HLI. PET imaging with [F]FtRGD provides a robust method for early detection of these proangiogenic effects preclinically and may be useful for the assessment of proangiogenic therapies used clinically to treat diabetic PAD patients.
外周动脉疾病(PAD)导致四肢动脉狭窄,导致组织缺血、坏疽,最终导致肢体截肢。糖尿病的存在极大地加剧了 PAD 的进程,占大多数下肢截肢的原因。聚焦于大血管修复的治疗策略在受影响较小血管的糖尿病患者中效果较差,而促血管生成治疗为这些高危人群改善血管化提供了可行的辅助手段。本研究的目的是使用多模态成像技术,在糖尿病小鼠后肢缺血模型中,从纵向角度评估常规用于治疗心血管疾病的药物的促血管生成作用。
糖尿病小鼠接受手术干预以诱导后肢缺血,并接受辛伐他汀、二甲双胍或联合口服治疗 28 天,并与糖尿病和非糖尿病小鼠进行比较。使用 [F]FtRGD PET 成像评估新生血管形成,使用定量飞行时间 MRI 评估大血管体积。在每个成像时间点,通过免疫组织化学分析量化 VEGF 表达和毛细血管密度,并评估功能恢复和疾病进展。
辛伐他汀和二甲双胍联合使用可显著增加新生血管形成,超过单独使用任何一种药物的水平。使用 PET [F]FtRGD 可准确评估早期血管生成事件,第 8 天缺血后肢的最大保留,随后在后期时间点持续增加血管体积。免疫组织化学分析表明,联合治疗可在相似的时间过程中显著增加 VEGF 表达和毛细血管密度(CD31),同时减缓疾病进展,同时改善足部功能使用。
辛伐他汀和二甲双胍联合治疗可显著改善糖尿病小鼠后肢缺血模型的肢体血管生成、血管体积和持续功能恢复。[F]FtRGD 的 PET 成像提供了一种在临床前早期检测这些促血管生成作用的强大方法,可能对评估用于治疗糖尿病 PAD 患者的临床促血管生成治疗有用。